Full history for every metric is available with a Kvantra account
Key financial summary
Financials in INRTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INR m | 1,673 | 2,024 | 1,371 | 1,296 | 1,043 | 1,424 | 251 | - |
| Operating profit | INR m | -134 | - | ||||||
| Net profit | INR m | 36 | 228 | -53 | -386 | -217 | -148 | -341 | - |
| EPS reported | INR | -6.80 | - | ||||||
| Operating cashflow per share | INR | -1.61 | - | ||||||
| Capex per share | INR | 1.61 | - | ||||||
| FCF per share | INR | 0.00 | - | ||||||
| Free cash flow | INR m | 0 | - | ||||||
| Net debt | INR m | 91 | - | ||||||
| Book value equity | INR m | 496 | - | ||||||
| Book value per share | INR | 9.90 | - | ||||||
| Number of shares | m | 50.13 | - | ||||||
| DPS (TTM paid) | INR | 0.00 | - |
Financial summary
Financials in INRTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.57 | - | ||||||
| P/S LTM | x | 1.13 | - | ||||||
| P/FCF LTM | x | 0.00 | - | ||||||
| EV/EBITDA LTM | x | -1.34 | - | ||||||
| EV/Sales LTM | x | 1.51 | - | ||||||
| Earnings Yield LTM | % | -119.93% | - | ||||||
| FCF Yield | % | 0.00% | - | ||||||
| Quality | |||||||||
| ROE | % | -68.70% | - | ||||||
| ROIC | % | -22.14% | - | ||||||
| Operating margin | % | -53.24% | - | ||||||
| Gross margin | % | -27.41% | - | ||||||
| FCF/Sales | % | 0.00% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -82.35% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | 0.00% | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | 0.00 | - | ||||||
| Net Debt/EBITDA | x | -0.34 | - | ||||||
| EBIT/Net interest | x | -34.66 | - | ||||||
| Net debt/market cap | % | 31.84% | - | ||||||
| Net debt/Equity | x | 0.18 | - | ||||||
| Gross debt/equity | x | 0.20 | - | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Lasa Supergenerics Limited is an Indian-based company that specializes in the research, development, production, and commercialization of healthcare products for both animals and humans, primarily serving the domestic market in India. Its core offerings include a diverse portfolio of Active Pharmaceutical Ingredients (APIs). These encompass a wide range of compounds such as fenbendazole, toldimphos sodium, cyromazine, albendazole, rafoxanide, ornidazole, oxfendazole, closantel base, nitroxynil, halquinol, and oxyclozanide, among many others, including specific chemicals like 2,6-diiodo-4-nitrophenol. Beyond APIs, the company also manufactures essential animal feed ingredients, notably calcium iodate, and supplies reagents for therapeutic applications, such as potassium iodide. The company additionally engages in the export of its various products, extending its reach beyond national borders. Established in 2016, Lasa Supergenerics Limited maintains its headquarters in Ratnagiri, India.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Lasa Supergenerics Limited (LASA.BO)
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Lasa Supergenerics Limited is an Indian-based company that specializes in the research, development, production, and commercialization of healthcare products for both animals and humans, primarily serving the domestic market in India. Its core offerings include a diverse portfolio of Active Pharmaceutical Ingredients (APIs). These encompass a wide range of compounds such as fenbendazole, toldimphos sodium, cyromazine, albendazole, rafoxanide, ornidazole, oxfendazole, closantel base, nitroxynil, halquinol, and oxyclozanide, among many others, including specific chemicals like 2,6-diiodo-4-nitrophenol. Beyond APIs, the company also manufactures essential animal feed ingredients, notably calcium iodate, and supplies reagents for therapeutic applications, such as potassium iodide. The company additionally engages in the export of its various products, extending its reach beyond national borders. Established in 2016, Lasa Supergenerics Limited maintains its headquarters in Ratnagiri, India.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free